A new generation of
artificial heart valves
designed to be *:

  • free of anticoagulant
  • for life
  • silent

Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease

 

 

  • An answer to a large unmet need worldwide

  • For patients of any age, including children

  • Design for the aortic & mitral valves

 

 Patient benefits

"I have been impressed by the Triflo valve and look forward to starting  first-in-human clinical trials.

This valve has the potential to benefit thousands of patients, especially young people."

Prof. Thierry Carrel, M.D.
University Hospital of Bern, Switzerland

 

Our key opinion leaders

 

This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 947344

Horizon 2020

 

(*) Caution: Novostia technology is an investigational device not yet approved for sale